Calyx Consulting

“An investment in knowledge pays the best interest.”
- Benjamin Franklin

Put Calyx’s experience to work for you.

Calyx is an industry leader in delivering the solutions pharmaceutical companies and Clinical Research Organizations (CROs) need to:

  • Improve the reliability of data when imaging biomarkers are used in clinical trials
  • Optimize randomization and trial supply management so trials run effectively
  • Ensure worldwide regulatory requirements are met, every time

Having supported over 650 new drug approvals, Calyx scientific, technical, and regulatory experts possess a depth and diversity of experience that’s unmatched and are prepared for whatever the drug development and regulatory compliance process throws at them.  Contact us now to learn how Calyx consultants can help you meet your development objectives and pave your way to success.

Meet the experts.

Extend the deep and diverse experience of Calyx’s highly tenured medical, scientific, and regulatory experts to your own clinical development team.

Minimize risks in clinical trial imaging, RTSM, and regulatory information management. Contact us today.

Library

Image Quantification in Neuro-Oncology Clinical Trials

Calyx Medical Imaging partners with Neosoma, an innovative medical technology company whose AI-based neuro-oncology software device is shown to achieve high accuracy in tumor volume measurement
Read more

Calyx Supports NMPA Approval of CAR-T Therapy for Multiple Myeloma

Calyx's support enabled CARsgen to demonstrate Zevor-cel’s profound and enduring therapeutic efficacy in patients with relapsed refractory multiple myeloma.
Read more

De-risking Prostate Cancer Trial Imaging

Medical imaging is a key study endpoint in prostate cancer trials, be it response-based or evaluating the time to recurrence or progress.
Read more

Assessing Prostate Cancer on Imaging in Clinical Trials

This whitepaper highlights Calyx’s expertise in using and adapting the PCWG3 criteria to address imaging-based objectives and endpoints in prostate cancer clinical trials.
Read more